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Gastro-oesophageal reflux disease
Impact of guidelines on GP management
Gastro-oesophageal reflux disease (GORD) is a highly 
prevalent condition characterised by regular and frequent 
‘heartburn’ and/or acid regurgitation.1 A recent epidemiological 
review has indicated that the prevalence of GORD in the 
western world is 10–20%.1 Gastro-oesophageal reflux disease 
is frequently managed in Australian general practice.2
In 2001 the Gastroenterological Society of Australia (GESA) released 
GORD management guidelines, which promoted history taking as 
the most useful method of diagnosis.3 They also recommended 
the use of once daily proton pump inhibitor (PPI) as initial therapy, 
on the basis that this provides high rates of symptom control and 
therefore provides useful diagnostic confirmation and usually prompt 
achievement of therapeutic aims. Just before this guideline release, 
PPIs were prescribed for approximately 18% of patients with gastric 
reflux.4 Other data from 2000 and 2001 indicates that 78% of patients 
with GORD were managing the disease with medication, including H2 
receptor antagonists (54%) and PPIs (29%).5 
 The implementation of clinical guidelines produced by authoritative 
bodies in clinical practice remains challenging, and is the focus of 
activity for the National Institute of Clinical Studies in Australia and 
the National Institute of Clinical Excellence in the United Kingdom.6–7
 Given the essential role of GPs in the detection and management 
of GORD, we explored ways to promote GP awareness and 
implementation of the evidence based GESA guidelines. 
 A second objective of this program was to examine the 
effectiveness of a five step clinical audit and feedback process in 
eliciting evidence based practice change in GP management of a high 
prevalence condition.
methods
The initial clinical audit was offered to GPs nationally over an 18 
month period from mid 2003. However, given the uptake and success 
of the audit, the audit was offered to GPs in February 2005, in 
Background
This program examined the impact of clinical guidelines and a 3 
year self audit process on general practitioners’ diagnosis and 
management of gastro-oesophageal reflux disease.
methods
Nine hundred and sixty-six Australian GPs participated in a 
retrospective five step clinical audit reporting on data for 28 622 
patients.
Results
General practitioners demonstrated significant improvements in their 
diagnosis and management of gastro-oesophageal reflux disease 
across the audit period, including:
•	 a	significant	3%	decrease	in	use	of	endoscopy
•	 	improved	GP	assessment	and	identification	of	risk	factors	and	
exacerbants
•	 	significant	increases	in	GP	recommendations	for	patient	weight	
loss	and	dietary	change	(7	and	10%	respectively)
•	 	a	significant	4%	reduction	in	patient	use	of	medications	that	may	
exacerbate reflux symptoms.
Discussion
The findings provide a snapshot of current diagnostic and 
management practices in Australian general practice, and highlight 
the benefits of clinical audit as a tool for eliciting evidence based, 
guideline driven practice change.
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conjunction with a related Reflux Nurse Review (RnR) program. The 
program was completed mid 2006. These two phases of the audit are 
referred to as ‘round 1’ and ‘round 2’ respectively.
 The clinical audit was developed over several stages, using input 
from a GORD working group and two focus groups with rural and 
metropolitan GPs, a comprehensive review of current guidelines and 
literature, and final piloting.
 The audit comprised five steps: pre-audit questionnaire; part 1 
audit sheets; reflection, education and practice change; part 2 audit 
sheets; and a final GP reflection on the activity. These steps enabled 
measurement of GPs’ clinical practices before commencing the audit 
(part 1), and any changes in clinical practice that occurred as a result 
of the audit and education process (part 2). 
 The pre-audit questionnaire comprised four questions regarding 
GPs’ motivations for participating in the audit, personal learning goals, 
current treatment of GORD, and awareness of the GESA guidelines.
 The part 1 audit sheets sought information about GPs’ past 
management of 20 patients aged 18 years and over who were 
currently being treated for GORD. General practitioners were 
instructed to search for and randomly select these patients from their 
records. Information required for each patient included methods of 
diagnosis, assessment and identification of GORD risk factors and 
exacerbants, and methods of treatment. 
 General practitioners were provided with a one page summary 
report containing their part 1 results and deidentified comparative 
data on their colleagues’ practices. Included with this report were 
a GP reflection survey and a copy of the GESA guidelines. The GP 
reflection survey comprised seven questions regarding GPs’ thoughts 
on their audit results, how they compared to the guidelines and areas 
for practice improvement. 
 The part 2 audit sheets sought identical information to that 
obtained from the part 1 sheets. Patients audited in part 2 were not 
necessarily the same as those audited in part 1; however, given that 
GPs were asked to randomly select patients seen within the past 6 
months, there may have been some overlap. 
 A summary report again provided GPs with their part 1 and 2 audit 
results and comparative data on their colleagues’ practices. Included 
with this report was a second GP reflection survey. The survey 
comprised 12 questions regarding GPs’ thoughts on their results, 
practice changes over the audit period, areas for further improvement 
and evaluation of the audit.
 Descriptive results were obtained to examine baseline clinical 
practices for all GPs who participated in the clinical audit. Given 
that the methodology was identical and there were no major 
circumstances or divergent results between audit rounds 1 and 2, 
data from both rounds were combined for analysis. Paired sample 
(two way) t-tests were then performed to compare part 1 and 2 audit 
results for GPs who completed the full audit to examine any practice 
changes that occurred as a result of audit participation. An estimated 
sample of 68 GPs was required to detect a moderate effect size (0.4, 
alpha = 0.05, with a power of 0.9 for correlated t-tests). 
 The project was approved by the Monash University Standing 
Committee on Ethics in Research Involving Humans (reference number 
2005/227).
Results
Nine hundred and sixty-six GPs across Australia participated in the 
first part of the audit and 467 completed the full audit process (52% 
attrition rate) (Table 1). General practitioners provided data on their 
management of GORD for 28 622 patients.
Descriptive results from all participating GPs
Table 2 presents a snapshot of GPs’ diagnostic and management 
practices at commencement of the audit. These results show the 
mean proportion (%) of patient cases in which GPs undertook each 
GORD diagnostic and management approach.
changes in GP practice across the audit process
Data from GPs who completed the full audit was analysed to examine 
practice changes that occurred as a result of their participation (Table 
3). Given the GP attrition rates, percentages rather than frequencies 
are presented.
Assessment and identification of GORD risk factors
There were significant increases in GPs’ assessment and recording 
of all audited risk factors for GORD (p<0.001). The results showed 
significant increases in GP identification of provocative dietary 
habits and overweight/obesity across the audit process (t[466]=3.82, 
p<0.001 and t[466]=4.70, p<0.001 respectively). However, increased 
assessment of GORD associated drugs and alert symptoms from 
audit parts 1 to 2 did not result in increased identification of the 
presence of these GORD risk factors (p>0.05).
Diagnosis of GORD
There was a significant 3% reduction in GP use of endoscopy from 
audit parts 1 to 2 (t[466]=2.95, p=0.003). There was no significant 
change in GP use of Barium swallows (p>0.05).
 There were significant increases in the assessment and identification 
of heartburn and regurgitation across the audit period (t[466]=2.45, 
p=0.015 and t[466]=4.53, p<0.001 respectively). Correspondingly, there 
was a significant reduction in ‘other’ methods of GORD diagnosis 
(t[466]=2.41, p=0.017).
GORD treatment
The results showed no significant change in GP prescription of PPIs 
or therapeutic drug trials across the audit period (p>0.05). There was, 
however, a nonsignificant trend toward increased PPI prescription 
(1.6%), representing approximately 300 patients.
 General practitioners reported a significant 4% reduction 
in H2 antagonist prescription (t[466]=5.60, p<0.001), while GP 
recommendations for antacids remained stable at 6% across the audit 
period (p>0.05). General practitioners also demonstrated increased 
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lifestyle modification as a means of improving patients’ GORD 
symptoms.
 The GESA guidelines also recommend PPIs as an appropriate 
therapy for the majority of patients displaying GORD symptoms, 
making it a key focal point for the clinical audit program. The rates of 
PPI prescription identified in this audit were considerably higher than 
rates from earlier Australian studies conducted from 1999 to 2001. 
recommendations for patient lifestyle modification. There were 
significant increases in GP recommendations for weight loss (6.8%) 
and dietary change (9.7%) from audit parts 1 to 2 (t[466]=7.15, p<0.001 
and (t[466]=7.21, p<0.001 respectively).
 The results also indicated a 3.9% increase in cases in which GPs 
reduced or ceased patients’ use of drugs that may exacerbate reflux 
induced symptoms (t[466]=4.22, p<0.001). General practitioner advice 
regarding posture also increased significantly 
(t[466]=3.08, p=0.002). Finally, there was a 
nonsignificant trend (1.4%) toward decreased 
specialist referrals (p>0.05). 
Discussion
The GORD clinical audit was successful in both 
engaging GPs and prompting beneficial changes 
in clinical practice. There were significant and 
meaningful changes in participating GPs’ 
assessment, diagnosis and management of GORD. 
This demonstrates that the clinical audit process, 
in association with promotion of evidence based 
guidelines, is an effective step toward positive GP 
practice change.
 There were clear improvements in GP 
assessment of GORD risk factors and exacerbants. 
While increased assessments did not always 
result in increased identification of risk factors, the 
results indicate that GPs had become more aware 
of, and active in, assessing patient risk factors and 
potential exacerbants for GORD. 
 General practitioners also appeared to rely less 
on invasive diagnostic investigations and became 
more focused on assessment of symptoms related 
directly to reflux episodes. These changes may 
impact considerably on the patient, with diagnosis 
becoming less reliant on invasive, costly and often 
ineffective endoscopy as an initial investigation.
 The findings also suggest that participation in 
the clinical audit process impacted considerably 
on several specific areas of GPs’ treatment of 
GORD. General practitioners reported more 
frequent recommendation of patient lifestyle 
modifications, including weight loss and dietary 
change, across the audit period. These results 
suggest that GPs had made an effort to encourage 
Table	1.	Breakdown	of	GP	participation	and	patient	data
Participation  Round 1  Round 2
Audit part 1 Audit part 2 Audit part 1 Audit part 2
GPs (n) 742 348 224 119
Patients (n) 14 761 7008 4458 2395
Table	2.	Diagnostic	and	management	practices	of	all	participating	GPs	(n=966)	at	
commencement of the audit
Parameter % of patients
Diagnosis 
Endoscopy 46.5
Barium swallow 5.8
Heartburn 60.5
Regurgitation 26.6
Other 19.7
Risk factors, risk management and exacerbants
Provocative eating/alcohol habits Not recorded 33.7
Recorded and absent 23.0
Recorded and present 43.3
GORD associated drugs Not recorded 22.3
Recorded and absent 45.5
Recorded and present 32.1
BMI >30 kg/m2 Not recorded 33.4
Recorded and absent 40.5
Recorded and present 26.1
Alert symptoms Not recorded 38.0
Recorded and absent 46.6
Recorded and present 15.4
initial management
Specialist referral 35.0
Reduce or cease GORD associated drugs 17.1
Weight loss 23.5
Therapeutic drug trial 59.6
Diet 39.5
Posture 18.9
None 5.6
current GORD drug prescribed 
Proton pump inhibitor 78.4
H2 antagonist 14.6
Antacid 6.0
None 5.4
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the audit sheets using the information recorded in their patient histories. 
Attempts were made to minimise attrition by regularly contacting 
participating GPs to provide materials, feedback and reminders.
 The encouraging findings from the clinical audit program highlight 
the impact of self audit, individualised feedback and reflection 
on GP management of a highly prevalent health condition. This 
research may also have implications for assessing the adoption of 
guidelines for other common conditions such as asthma, diabetes and 
cardiovascular disease.
implications for general practice
•	The	clinical	audit	process	can	assist	the	implementation	of	clinical	
guidelines for high prevalence conditions in general practice.
Only a small, nonsignificant increase in GPs’ PPI prescription was 
observed across the period of this clinical audit. General practitioners’ 
increased recommendations for lifestyle modifications showed that 
they were willing to adopt other initial treatments rather than simply 
increasing their prescription of PPIs.
 General practitioners also demonstrated positive changes in other 
areas of their GORD treatment practices, including offering more 
advice about posture, and decreasing patients’ use of medications that 
might exacerbate GORD symptoms.  
 It is important to note that the results must be interpreted in light 
of methodological limitations including reliability of self report, patient 
selection biases and GP attrition. To minimise these limitations, GPs were 
instructed to randomly select patients from their records and complete 
Table	3.	Diagnostic	and	management	practices	of	GPs	who	completed	the	full	audit	(n=467)
Parameter Audit part 1
% of patients
Audit part 2
% of patients
Diagnosis
Endoscopy 48.0 44.9**
Barium swallow 6.4  5.6
Heartburn 60.1 63.1*
Regurgitation 27.5  32.4†
Other 18.8  16.2*
Risk factors, risk management and exacerbants
Provocative eating/alcohol habits Not recorded 32.3  19.0†
Recorded and absent 24.0  32.6†
Recorded and present 43.7  48.3†
GORD associated drugs Not recorded 21.3  13.8†
Recorded and absent 46.1  53.9†
Recorded and present 32.6  32.2
BMI >30 kg/m2 Not recorded 31.6  20.5†
Recorded and absent 41.2  48.3†
Recorded and present 27.2  31.2†
Alert symptoms Not recorded 37.4  23.0†
Recorded and absent 46.3  60.2†
Recorded and present 16.3  16.8
initial management
Specialist referral 34.6  33.2
Reduce or cease GORD associated drugs 17.7  21.6†
Weight loss 24.5  31.3†
Therapeutic drug trial 60.2  60.9
Diet 40.3  50.0†
Posture 20.3  24.3**
None 5.5  3.4**
current GORD drug prescribed 
Proton pump inhibitor 77.8  79.4
H2 antagonist 15.2  11.1
†
Antacid 5.9  6.1
None 5.6  7.4**
* p<0.05 ** p<0.01 † p<0.001
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•	Clinical	 audits	 may	 be	 a	 useful	 tool	 for	 both	 promoting	 and	
assessing guideline driven practice change in general practice.
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